Screener
ArriVent BioPharma, Inc. AVBP Deferred contract costs
Deferred contract costs at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredCosts.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 22,320 | 20,076 |
| Total current assets | 348,700 | 332,897 |
| Right of use assets – operating leases | 370 | 13 |
| Deferred offering costs | 69 | 69 |
| Other assets | 156 | 190 |
| Total assets | $349,295 | $333,169 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s deferred contract costs?
- ArriVent BioPharma, Inc. (AVBP) reported deferred contract costs of $69K in Q1 2026.
- What does deferred contract costs mean?
- Deferred contract costs represent incremental costs incurred to obtain or fulfill a contract that are expected to be recovered over a period exceeding one year. In the biopharmaceutical industry, these often relate to capitalized costs associated with long-term collaboration agreements or licensing arrangements. This metric reflects the company's investment in securing future revenue streams and is amortized over the expected duration of the underlying contract.
Ask your AI about ArriVent BioPharma, Inc.'s deferred contract costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude